Indegene IPO

Indegene Ltd

₹14,190 /33 sharesMinimum Investment

Indegene IPO Listing Details

Listed OnIssue PriceListing PriceListing Gains
BSE₹452.00₹655.00₹203.00 (44.91%)

Indegene IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
6 May ‘24 - 8 May ‘24₹14,19033₹430 - ₹452
Issue SizeIPO Doc
1841.76Cr
RHP PDF

Subscription rate

As of 08 May'24, 04:00 PM
Qualified Institutional Buyers139.1x
Non-Institutional Investor49.79x
Retail Individual Investor6.94x
Employees5.42x
Total52.27x

About the company

Indegene Limited provides digital-led commercialization services for the life sciences industry, specifically catering to biopharmaceutical, emerging biotech and medical devices companies. The company assistance in drug development, clinical trials, pharmacovigilance, regulatory submissions, complaints management, and sales/marketing. The company’s solutions enable its client companies to develop and sell products through their life cycle in a more effective, efficient and modern manner. The company offers Enterprise Commercial Solutions and Omnichannel Activation solutions to address the commercial needs of life sciences companies. It also offers Enterprise Medical Solutions and Enterprise Clinical Solutions to support the medical and R&D functions of its client companies.;
Founded in
1998
Managing director
Mr. Manish Gupta
Parent organisation
Indegene Ltd
Indegene Ltd IPO
https://www.youtube.com/watch?v=kjKRpoxL9OQ

Strength and risks

Strengths
Risks
As of December 31, 2023, the company had 65 active clients. It provides solutions to these clients from its operation hubs situated across North America, Europe, and Asia.
As per the company’s RHP, it maintains long-standing relationships with major biopharmaceutical firms, including each of the 20 largest biopharmaceutical companies globally by revenue for the 2023 financial year.
The company meets its clients' needs through six operation hubs and 17 offices spread across North America, Europe, and Asia.
As per the company, it has completed several acquisitions since 2005, leveraging the synergies, networks, technologies, and talent pools of the acquired companies to its advantage.
The company reported revenue from operations of Rs. 966.27 cr, Rs. 1,664.6 cr and Rs. 2,306.13 cr in FY 2021, 2022 and 2023 respectively. For the same time periods, it reported Profit after tax of Rs. 185.68 cr, Rs. 162.81 cr and Rs. 266.09 cr respectively.

Financials

*All values are in Rs. Cr
No Graph Data To Display

Application details

Apply asPrice bandApply upto
Regular430 - 452₹2 Lakh
Employee400 - 422₹2 Lakh
High Networth Individual430 - 452₹2 - 5 Lakh
For Indegene IPO, eligible investors can apply as Regular & Employee.
ⓒ 2016-2024 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 5.0.5
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  IDFC |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ

ABOUT GROWW